ArticleWorld journal of pediatrics : WJP2025
Development of a low-cost and high-throughput LC-MS method for newborn screening of thalassemia and abnormal hemoglobin disorders.
Article in World journal of pediatrics : WJP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.International journal of neonatal screening · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundScreening and pre-symptomatic diagnosis in newborns allows early treatment of thalassemia and abnormal hemoglobin (Hb) disorders in childhood. However, there remains a lack of efficient methods to screen for hemoglobinopathies in newborns. This study aimed to establish a bottom-up mass spectrometry (MS)-based method for efficient screening of hemoglobinopathies in newborns using dried blood spot (DBS) samples.
methodsWe developed LC-MS methodology using high-performance liquid chromatography (HPLC) combined with high-resolution mass spectrometry (HRMS). DBS samples from patients covering the most common types of hemoglobinopathies and normal controls were collected. We extracted Hb from a 3.2 mm disc punched from the DBS sample, which was then digested with trypsin to release a series of Hb-specific peptides. Using HPLC-HRMS, we identified disease-related peptides for biomarker design. Using this methodology, we built a prediction model using binary logistic regression to facilitate efficient screening.
resultsThis new method costs less than $1 per test and can process at least 192 samples per batch. Our methodology is fast with a sampling and analysis time of 2.6 minutes and inter- and intra-assay coefficients of variation below 14.67%. Moreover, we report low limits of quantification for the proteo-specific peptides (0.50-60.00 μg/L). No significant matrix effects or carryover were observed. Our method could give reliable results even with DBS samples stored for one month. Prospective application of this method to 2726 newborns identified 87 patients with hemoglobinopathies and achieved high screening sensitivity and specificity for deletional α-thalassemia (--
conclusionsWe have developed a low-cost, high-throughput method for reliable screening of thalassemia and abnormal Hb disorders in newborns. This could be deployed as a first-line screening test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.